The invention relates to a novel use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having both neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP), and endothelin convertase (ECE), inhibitory activity. The compounds of this invention are useful for the preparation of pharmaceutical compositions to reduce harmful effects of symptomless progressive disseminated perfusion deficiency of organs, or parts thereof, that may be suggestive of systemic diseases.

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic -keto amide derivatives and their use as therapeutic agents.

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula:

##STR00001##

wherein, R.sup.1 is a 5- to 6-membered ring group which may be substituted; X.sup.1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X.sup.2 is a bivalent group of 1 to 4 atoms; Z.sup.1 is a bivalent cyclic ring group or the like; Z.sup.2 is a bond or the like; and R.sup.2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula:

##STR00001##

wherein, R.sup.1 is a 5- to 6-membered ring group which may be substituted; X.sup.1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X.sup.2 is a bivalent group of 1 to 4 atoms; Z.sup.1 is a bivalent cyclic ring group or the like; Z.sup.2 is a bond or the like; and R.sup.2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

The disclosure includes high purity compounds having CCR5 and/or CCR2 antagonism, or a salt thereof, and processes for synthesizing the same.

The disclosure includes high purity compounds having CCR5 and/or CCR2 antagonism, or a salt thereof, and processes for synthesizing the same.

The invention relates to a compound capable of blocking the absorption of heavy metals by plants and a composition containing the same. The compound was extracted from Aegiceras corniculatum. The compound is extracted by enzyme extraction, filtration, concentrating and drying. The compound is derived from natural plants, and no organic solvents are used in the extraction process. The compound and the composition formed by the compound have a certain barrier effect on the absorption of heavy metals by plants.

##STR00001##

The invention relates to a compound capable of blocking the absorption of heavy metals by plants and a composition containing the same. The compound was extracted from Aegiceras corniculatum. The compound is extracted by enzyme extraction, filtration, concentrating and drying. The compound is derived from natural plants, and no organic solvents are used in the extraction process. The compound and the composition formed by the compound have a certain barrier effect on the absorption of heavy metals by plants.

##STR00001##

Provided is a method for producing an optically active substance, the method including an asymmetric induction, wherein an asymmetry inducer is allowed to act on a chiral molecule having a half-life of enantiomeric excess of shorter than 10 hours, thereby increasing abundance of one enantiomer of the chiral molecule. According to this method, one enantiomer of a chiral molecule that is susceptible to racemization can be selectively and efficiently obtained.

The disclosure includes high purity compounds having CCR5 and/or CCR2 antagonism, or a salt thereof, and processes for synthesizing the same.